Home » Newsletters » BioWorld Science

BioWorld Science

April 11, 2008

View Archived Issues

Indibulin well tolerated, active in patients with advanced solid tumors

DTS-108 may represent an improvement over irinotecan

Abacavir, didanosine linked to increased risk of myocardial infarction

Nebicapone increases levodopa exposure in Parkinson's disease patients

PHX-1149 effective in proof-of-concept study in type 2 diabetes patients

Collegium filed supplemental NDA for approval of AllerNase for allergic rhinitis

Phase I study of ENMD-2076 begins in advanced cancer patients

Otelixizumab set to enter phase III for new-onset type 1 diabetes

Cationorm launched in France for dry eye symptoms

Novel CGRP antagonist profiled at Merck & Co.

Iomai receives grant to develop patch-based anthrax vaccine

Critical Therapeutics completes phase I clinical trial of (R)-zileuton

Exubera labeling updated in the United States

Seattle Genetics initiates phase Ib clinical trial of SGN-40 in non-Hodgkin's lymphoma

Novartis' ACZ-885 shows potential in treating serious life-long autoinflammatory conditions

Teverelix LA demonstrates testosterone suppression in prostate cancer study

BGC-20-0166 shows potential for obstructive sleep apnea

OVax cleared to begin phase I/II trial in ovarian cancer

Aerosolized ALN-RSV01 begins phase II trial in adult RSV

Pivotal phase III trial commences for novel cancer agent ASA-404

FDA approves Lexiscan as an agent in myocardial perfusion imaging

Crucell enters research license agreement with Celltrion to evaluate Star production technology

FDA extends action date for priority review of Amgen's BLA for romiplostim in ITP

Recent patents disclose novel antidiabetic agents

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...